南卡羅來納州 的 急性髓系白血病 臨床試驗
16 項針對 急性髓系白血病 的研究正在 南卡羅來納州 各地點尋找參與者。
南卡羅來納州 的城市
官方研究文本（英文）
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- 還有 5 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年10月5日 · NCT05564390Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AnMed Health Cancer Center, Anderson
- Prisma Health Richland Hospital, Columbia
- McLeod Regional Medical Center, Florence
- 還有 12 項
招募中觀察性研究歡迎健康志工
40 至 75 歲 · 所有性別 · 更新於 2026年10月2日 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Cancer Institute - Easley, Easley
- Prisma Health Cancer Institute - Butternut, Greenville
- 還有 4 項
招募中2 期
18 至 59 歲 · 所有性別 · 更新於 2026年9月28日 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Cancer Institute - Easley, Easley
- Prisma Health Cancer Institute - Butternut, Greenville
- 還有 4 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月22日 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- 還有 5 項
招募中2 期
18 至 59 歲 · 所有性別 · 更新於 2026年9月22日 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- 還有 5 項
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月22日 · NCT06317649A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
招募中3 期
6 Months – 21 Years · 所有性別 · 更新於 2026年9月17日 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- MUSC Health University Medical Center, Charleston
招募中2 期
18 歲及以上 · 所有性別 · 更新於 2026年9月15日 · NCT04996875Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Bon Secours St. Francis Cancer Center, Greenville
招募中1/2 期
12 歲及以上 · 所有性別 · 更新於 2026年9月3日 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Medical University of South Carolina, Charleston
- Prisma Health Richland Hospital, Columbia
- BI-LO Charities Children's Cancer Center, Greenville
招募中1/2 期
22 歲以下 · 所有性別 · 更新於 2026年8月25日 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Prisma Health Richland Hospital, Columbia
招募中3 期
29 Days – 21 Years · 所有性別 · 更新於 2026年8月24日 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Prisma Health, Greenville
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年8月20日 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical University of South Carolina, Charleston
招募中觀察性研究
所有年齡 · 所有性別 · 更新於 2026年7月6日 · NCT01351545Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- Medical University of South Carolina, Charleston
招募中1 期
18 歲及以上 · 所有性別 · 更新於 2026年6月15日 · NCT02074839A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Hollings Cancer Center, Charleston
招募中2/3 期
18 歲及以上 · 所有性別 · 更新於 2026年4月30日 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Medical University of South Carolina, Charleston
招募中1/2 期
12 歲及以上 · 所有性別 · 更新於 2026年3月24日 · NCT04988555資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。